NASDAQ · HURA
Healthcare · Biotechnology
$2.04
Up+$0.01 (+0.25%)
Updated Oct 27, 2026, 1:42 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HURA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
HURA closed at $2.04 after 21 trading sessions, down 2.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $2.205 | $2.23 | $1.9301 | $2.04 | 636.51K |
| Oct 23, 2026 | $2.07 | $2.185 | $2.05 | $2.18 | 1.01M |
| Oct 22, 2026 | $2.20 | $2.20 | $1.96 | $2.01 | 609.26K |
| Oct 21, 2026 | $1.74 | $2.1099 | $1.71 | $2.085 | 1.08M |
| Oct 20, 2026 | $1.77 | $1.81 | $1.75 | $1.76 | 39.15K |
| Oct 19, 2026 | $1.75 | $1.96 | $1.74 | $1.78 | 173.44K |
| Oct 16, 2026 | $1.81 | $1.85 | $1.76 | $1.76 | 86.04K |
| Oct 15, 2026 | $1.74 | $1.84 | $1.74 | $1.83 | 86.69K |
| Oct 14, 2026 | $1.78 | $1.78 | $1.7107 | $1.76 | 144.98K |
| Oct 13, 2026 | $1.91 | $1.91 | $1.80 | $1.81 | 354.66K |
| Oct 12, 2026 | $1.97 | $1.99 | $1.89 | $1.90 | 170.6K |
| Oct 9, 2026 | $1.95 | $1.99 | $1.95 | $1.96 | 148.97K |
| Oct 8, 2026 | $1.95 | $1.97 | $1.89 | $1.93 | 316.37K |
| Oct 7, 2026 | $1.91 | $2.00 | $1.871 | $1.98 | 140.45K |
| Oct 6, 2026 | $1.90 | $1.98 | $1.87 | $1.95 | 181.7K |
| Oct 5, 2026 | $1.94 | $1.94 | $1.85 | $1.87 | 335.53K |
| Oct 2, 2026 | $2.00 | $2.0499 | $1.88 | $1.91 | 287.78K |
| Oct 1, 2026 | $2.09 | $2.10 | $1.97 | $1.98 | 273.6K |
| Sep 30, 2026 | $2.06 | $2.175 | $2.06 | $2.10 | 284.47K |
| Sep 29, 2026 | $2.08 | $2.12 | $2.035 | $2.07 | 231.3K |
| Sep 28, 2026 | $2.06 | $2.16 | $2.03 | $2.09 | 375.39K |
The latest Smart Investors Daily articles mentioning HURA.
Company
Market Activity
Research & News
HURA research
Company profile and research snapshot.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Citizens | Market Outperform | — |
| Apr 27, 2026 | Citizens | Market Outperform | — |
| Feb 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2025 | Maxim Group | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 13, 2026
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. 12,760,104 entitled, "Anti-VISTA Antibodies and Uses Thereof."
Benzinga · Oct 13, 2026
Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodiesTAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the
Yahoo · Oct 5, 2026
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,168 entitled, "Delta Opioid Receptor Antagonists Reprogram Immunosuppresive Microenvironment to Boost Immunotherapy." The patent is directed to, among other things, administration of DOR antagonists to subjects having c
Benzinga · Oct 5, 2026
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HURA.
